CT and CEST MRI bimodal imaging of the intratumoral distribution of iodinated liposomes

Zelong Chen, Yuguo Li, Raag Airan, Zheng Han, Jiadi Xu, Kannie W.Y. Chan, Yikai Xu, Jeff W.M. Bulte, Peter C.M. Van Zijl, Michael T. McMahon, Shibin Zhou, Guanshu Liu

Research output: Contribution to journalArticle

Abstract

Background: To develop liposomes loaded with iodinated agents as nanosized CT/MRI bimodal contrast agents for monitoring liposome-mediated drug delivery. Methods: Rhodamine-labeled iodixanol (VisipaqueTM)-loaded liposomes (IX-lipo) were prepared and tested for their properties as a diamagnetic CEST contrast agent in vitro. Mice bearing subcutaneous CT26 colon tumors were injected i.v. with 1 g/kg (535 mg iodine/kg) IX-lipo, and in vivo CT and CEST MR images were acquired on day 3. CT and CEST MR images were also acquired for tumor-bearing mice co-injected with IX-lipo and tumor necrosis factor (TNF-α). Results: In addition to CT contrast, IX-lipo exhibited a strong CEST contrast similar to its non-liposomal form, with a detectability of ~2 nM per liposome. Both CT imaging and CEST MRI showed that i.v. injection of IX-lipo resulted in a rim enhancement of CT26 tumors with a heterogeneous central distribution. In contrast, coinjection of TNF-α caused a significantly augmented CT/MRI contrast in the tumor center. The intratumoral biodistribution of IX-lipo correlated well to the rhodamine patterns observed with fluorescence microscopy. Conclusions: We have developed a CT/MRI bimodal imaging approach for monitoring the delivery and biodistribution of liposomes by loading them with the clinically approved X-ray/CT contrast agent iodixanol. Our approach may be easily adapted for other-FDA approved iodinated agents and thus has great translational potential.

Original languageEnglish (US)
Pages (from-to)1579-1591
Number of pages13
JournalQuantitative Imaging in Medicine and Surgery
Volume9
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Liposomes
Contrast Media
Rhodamines
Neoplasms
X Ray Computed Tomography
Fluorescence Microscopy
Iodine
Colon
Tumor Necrosis Factor-alpha
Injections
Pharmaceutical Preparations
iodixanol

Keywords

  • Chemical exchange saturation transfer magnetic resonance imaging (CEST MRI)
  • Computed tomography (CT)
  • Enhanced permeability and retention effect (EPR effect)
  • Iodixanol
  • Liposomes
  • Vascular-targeting therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

CT and CEST MRI bimodal imaging of the intratumoral distribution of iodinated liposomes. / Chen, Zelong; Li, Yuguo; Airan, Raag; Han, Zheng; Xu, Jiadi; Chan, Kannie W.Y.; Xu, Yikai; Bulte, Jeff W.M.; Van Zijl, Peter C.M.; McMahon, Michael T.; Zhou, Shibin; Liu, Guanshu.

In: Quantitative Imaging in Medicine and Surgery, Vol. 9, No. 9, 01.01.2019, p. 1579-1591.

Research output: Contribution to journalArticle

@article{6e0a9d92650540b8aecb7b542ab76c99,
title = "CT and CEST MRI bimodal imaging of the intratumoral distribution of iodinated liposomes",
abstract = "Background: To develop liposomes loaded with iodinated agents as nanosized CT/MRI bimodal contrast agents for monitoring liposome-mediated drug delivery. Methods: Rhodamine-labeled iodixanol (VisipaqueTM)-loaded liposomes (IX-lipo) were prepared and tested for their properties as a diamagnetic CEST contrast agent in vitro. Mice bearing subcutaneous CT26 colon tumors were injected i.v. with 1 g/kg (535 mg iodine/kg) IX-lipo, and in vivo CT and CEST MR images were acquired on day 3. CT and CEST MR images were also acquired for tumor-bearing mice co-injected with IX-lipo and tumor necrosis factor (TNF-α). Results: In addition to CT contrast, IX-lipo exhibited a strong CEST contrast similar to its non-liposomal form, with a detectability of ~2 nM per liposome. Both CT imaging and CEST MRI showed that i.v. injection of IX-lipo resulted in a rim enhancement of CT26 tumors with a heterogeneous central distribution. In contrast, coinjection of TNF-α caused a significantly augmented CT/MRI contrast in the tumor center. The intratumoral biodistribution of IX-lipo correlated well to the rhodamine patterns observed with fluorescence microscopy. Conclusions: We have developed a CT/MRI bimodal imaging approach for monitoring the delivery and biodistribution of liposomes by loading them with the clinically approved X-ray/CT contrast agent iodixanol. Our approach may be easily adapted for other-FDA approved iodinated agents and thus has great translational potential.",
keywords = "Chemical exchange saturation transfer magnetic resonance imaging (CEST MRI), Computed tomography (CT), Enhanced permeability and retention effect (EPR effect), Iodixanol, Liposomes, Vascular-targeting therapy",
author = "Zelong Chen and Yuguo Li and Raag Airan and Zheng Han and Jiadi Xu and Chan, {Kannie W.Y.} and Yikai Xu and Bulte, {Jeff W.M.} and {Van Zijl}, {Peter C.M.} and McMahon, {Michael T.} and Shibin Zhou and Guanshu Liu",
year = "2019",
month = "1",
day = "1",
doi = "10.21037/qims.2019.06.10",
language = "English (US)",
volume = "9",
pages = "1579--1591",
journal = "Quantitative Imaging in Medicine and Surgery",
issn = "2223-4292",
publisher = "AME Publishing Company",
number = "9",

}

TY - JOUR

T1 - CT and CEST MRI bimodal imaging of the intratumoral distribution of iodinated liposomes

AU - Chen, Zelong

AU - Li, Yuguo

AU - Airan, Raag

AU - Han, Zheng

AU - Xu, Jiadi

AU - Chan, Kannie W.Y.

AU - Xu, Yikai

AU - Bulte, Jeff W.M.

AU - Van Zijl, Peter C.M.

AU - McMahon, Michael T.

AU - Zhou, Shibin

AU - Liu, Guanshu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: To develop liposomes loaded with iodinated agents as nanosized CT/MRI bimodal contrast agents for monitoring liposome-mediated drug delivery. Methods: Rhodamine-labeled iodixanol (VisipaqueTM)-loaded liposomes (IX-lipo) were prepared and tested for their properties as a diamagnetic CEST contrast agent in vitro. Mice bearing subcutaneous CT26 colon tumors were injected i.v. with 1 g/kg (535 mg iodine/kg) IX-lipo, and in vivo CT and CEST MR images were acquired on day 3. CT and CEST MR images were also acquired for tumor-bearing mice co-injected with IX-lipo and tumor necrosis factor (TNF-α). Results: In addition to CT contrast, IX-lipo exhibited a strong CEST contrast similar to its non-liposomal form, with a detectability of ~2 nM per liposome. Both CT imaging and CEST MRI showed that i.v. injection of IX-lipo resulted in a rim enhancement of CT26 tumors with a heterogeneous central distribution. In contrast, coinjection of TNF-α caused a significantly augmented CT/MRI contrast in the tumor center. The intratumoral biodistribution of IX-lipo correlated well to the rhodamine patterns observed with fluorescence microscopy. Conclusions: We have developed a CT/MRI bimodal imaging approach for monitoring the delivery and biodistribution of liposomes by loading them with the clinically approved X-ray/CT contrast agent iodixanol. Our approach may be easily adapted for other-FDA approved iodinated agents and thus has great translational potential.

AB - Background: To develop liposomes loaded with iodinated agents as nanosized CT/MRI bimodal contrast agents for monitoring liposome-mediated drug delivery. Methods: Rhodamine-labeled iodixanol (VisipaqueTM)-loaded liposomes (IX-lipo) were prepared and tested for their properties as a diamagnetic CEST contrast agent in vitro. Mice bearing subcutaneous CT26 colon tumors were injected i.v. with 1 g/kg (535 mg iodine/kg) IX-lipo, and in vivo CT and CEST MR images were acquired on day 3. CT and CEST MR images were also acquired for tumor-bearing mice co-injected with IX-lipo and tumor necrosis factor (TNF-α). Results: In addition to CT contrast, IX-lipo exhibited a strong CEST contrast similar to its non-liposomal form, with a detectability of ~2 nM per liposome. Both CT imaging and CEST MRI showed that i.v. injection of IX-lipo resulted in a rim enhancement of CT26 tumors with a heterogeneous central distribution. In contrast, coinjection of TNF-α caused a significantly augmented CT/MRI contrast in the tumor center. The intratumoral biodistribution of IX-lipo correlated well to the rhodamine patterns observed with fluorescence microscopy. Conclusions: We have developed a CT/MRI bimodal imaging approach for monitoring the delivery and biodistribution of liposomes by loading them with the clinically approved X-ray/CT contrast agent iodixanol. Our approach may be easily adapted for other-FDA approved iodinated agents and thus has great translational potential.

KW - Chemical exchange saturation transfer magnetic resonance imaging (CEST MRI)

KW - Computed tomography (CT)

KW - Enhanced permeability and retention effect (EPR effect)

KW - Iodixanol

KW - Liposomes

KW - Vascular-targeting therapy

UR - http://www.scopus.com/inward/record.url?scp=85076438449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076438449&partnerID=8YFLogxK

U2 - 10.21037/qims.2019.06.10

DO - 10.21037/qims.2019.06.10

M3 - Article

C2 - 31667143

AN - SCOPUS:85076438449

VL - 9

SP - 1579

EP - 1591

JO - Quantitative Imaging in Medicine and Surgery

JF - Quantitative Imaging in Medicine and Surgery

SN - 2223-4292

IS - 9

ER -